Publications

Authors:

Schweiger, Vittorio; Bellamoli, Paola; Taus, Francesco; Gottin, Leonardo; Martini, Alvise; Nizzero, Marta; Bonora, Eleonora; Del Balzo, Giovanna; Donadello, Katia; Secchettin, Erica; Finco, Gabriele; Santis, Daniele De; Polati, Enrico

Title:

Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

JOURNAL OF CLINICAL MEDICINE

ISSN of journal:

2077-0383

N° Volume:

13

Number or Folder:

4

Page numbers:

1-10

Keyword:

calcitonin gene-related peptide (CGRP); migraine; monoclonal antibodies; prophylaxis

Short description of contents:

Background: Migraine is a neurological disorder characterized by attacks of head pain with prevalent unilateral localization, moderate to high intensity and specifically associated accompanying symptoms. Methods: In this retrospective observational study, we analyzed data regarding 209 patients who had previously been diagnosed with migraine and who were prescribed, between 2019 and 2022, subcutaneous injections of anti-CGRP monoclonal antibodies (mAbs) fremanezumab or galcanezumab or anti-CGRP receptors mAb erenumab regardless of the concomitant assumption of any other acute-phase or prophylactic migraine medication. Results: Regarding efficacy, in the 205 analyzed patients, the change from baseline in terms of MIDAS, HIT-6, MMDs and MAD scores was statistically significant for erenumab and galcanezumab, while for fremanezumab a statistical significance was not achieved likely due to the small sample size. In the treated population, 36 patients (17.5%) reported AEs (pain during injection, transient injection site erythema, nausea, constipation and fatigue). Only 5 patients (2.4%) discontinued the treatment for AEs while 15 patients (7.3%) left for lack of efficacy. Conclusions: this retrospective study comes out in favor of both significant efficacy and safety of anti-CGRP and anti-CGRP receptors mAbs in migraine patients. Further methodologically stronger studies are necessary to validate our observation.

Product ID:

139226

Handle IRIS:

11562/1125469

Last Modified:

May 3, 2024

Bibliographic citation:

Schweiger, Vittorio; Bellamoli, Paola; Taus, Francesco; Gottin, Leonardo; Martini, Alvise; Nizzero, Marta; Bonora, Eleonora; Del Balzo, Giovanna; Donadello, Katia; Secchettin, Erica; Finco, Gabriele; Santis, Daniele De; Polati, Enrico, Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients «JOURNAL OF CLINICAL MEDICINE» , vol. 13 , n. 4 , 2024 , pp. 1-10

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo